These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 34416)

  • 41. Calculated nitrogen balance in hemodialysis patients: influence of protein intake.
    Rao M; Sharma M; Juneja R; Jacob S; Jacob CK
    Kidney Int; 2000 Jul; 58(1):336-45. PubMed ID: 10886580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of narcotic drugs, tranquilizers, amphetamines, and barbiturates in urine.
    Dole VP; Kim WK; Eglitis I
    JAMA; 1966 Oct; 198(4):349-52. PubMed ID: 5953253
    [No Abstract]   [Full Text] [Related]  

  • 43. The origin of the "ideal" body weight equations.
    Pai MP; Paloucek FP
    Ann Pharmacother; 2000 Sep; 34(9):1066-9. PubMed ID: 10981254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Silicon metabolism. I. Some aspects of renal silicon handling in normal man.
    Berlyne GM; Adler AJ; Ferran N; Bennett S; Holt J
    Nephron; 1986; 43(1):5-9. PubMed ID: 3703066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
    Westerbacka J; Yki-Järvinen H; Vehkavaara S; Häkkinen AM; Andrew R; Wake DJ; Seckl JR; Walker BR
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4924-31. PubMed ID: 14557475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GC/MS confirmation of barbiturates in blood and urine.
    Meatherall R
    J Forensic Sci; 1997 Nov; 42(6):1160-70. PubMed ID: 9397563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of flurbiprofen on renal function in patients with moderate renal insufficiency.
    Murray MD; Greene PK; Brater DC; Manatunga AK; Hall SD
    Br J Clin Pharmacol; 1992 Apr; 33(4):385-93. PubMed ID: 1576067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isomerisation and urinary excretion of proxibarbal and valofan in man; a preliminary study.
    Wittekind HH; Testa B; Balant LP
    Eur J Drug Metab Pharmacokinet; 1984; 9(2):117-22. PubMed ID: 6146529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sodium valproate stimulates potassium and chloride urinary excretion in rats: gender differences.
    Jakutiene E; Grikiniene J; Vaitkevicius A; Tschaika M; Didziapetriene J; Stakisaitis D
    BMC Pharmacol; 2007 Aug; 7():9. PubMed ID: 17683602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exclusion of urinary barbiturates by gas chromatography.
    Blackmore DJ; Jenkins RW
    J Forensic Sci Soc; 1968 Jan; 8(1):34-7. PubMed ID: 5666505
    [No Abstract]   [Full Text] [Related]  

  • 52. The urinary excretion of enibomalum (NFN) in man after administration of anaesthetic doses.
    Ravn-Jonsen A
    Acta Pharmacol Toxicol (Copenh); 1970; 28(6):484-92. PubMed ID: 5536782
    [No Abstract]   [Full Text] [Related]  

  • 53. Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (BCP) in man. IV. Pharmacokinetics of BCP in man following oral administration.
    Yashiki T; Matsuzawa T; Yamada M; Kondo T; Uda Y
    Chem Pharm Bull (Tokyo); 1971 May; 19(5):869-80. PubMed ID: 5557927
    [No Abstract]   [Full Text] [Related]  

  • 54. Lean body mass as a predictor of drug dosage. Implications for drug therapy.
    Morgan DJ; Bray KM
    Clin Pharmacokinet; 1994 Apr; 26(4):292-307. PubMed ID: 8013162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The distribution of amylobarbitone, butobarbitone, pentobarbitone and quinalbarbitone and the hydroxylated metabolites in man.
    Robinson AE; McDowall RD
    J Pharm Pharmacol; 1979 Jun; 31(6):357-65. PubMed ID: 39132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A kinetic study of human urinary excretion results for butobarbitone and its metabolites.
    Gilbert JN; Natunen T; Powell JW; Saunders L
    J Pharm Pharmacol; 1974 Dec; 26 Suppl():16P-23P. PubMed ID: 4156729
    [No Abstract]   [Full Text] [Related]  

  • 57. Mass spectrometric determination of butobarbitone and its metabolites in man.
    Gilbert JN; Powell JW
    Biomed Mass Spectrom; 1974 Apr; 1(2):142-4. PubMed ID: 4433727
    [No Abstract]   [Full Text] [Related]  

  • 58. Cimetidine disposition in obesity.
    Abernethy DR; Greenblatt DJ; Matlis R; Gugler R
    Am J Gastroenterol; 1984 Feb; 79(2):91-4. PubMed ID: 6364798
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight.
    Cheymol G; Bernheim C; Besson J; Dry J; Portet R
    Br J Clin Pharmacol; 1979 Mar; 7(3):303-9. PubMed ID: 34416
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.